Please login to the form below

Not currently logged in
Email:
Password:

Invokana

This page shows the latest Invokana news and features for those working in and with pharma, biotech and healthcare.

J&J’s Invokana aces diabetic kidney disease trial, setting up filings

J&J’s Invokana aces diabetic kidney disease trial, setting up filings

The large-scale CREDENCE trial pitted Invokana (canagliflozin) against placebo in type 2 diabetics with established CKD on top of standard therapy. ... a big new market at a time when Invokana is feeling the pinch.

Latest news

  • J&J says real-world data finds no amputation risk for Invokana J&J says real-world data finds no amputation risk for Invokana

    J&J says real-world data finds no amputation risk for Invokana. Hopes the new data will persuade regulators to ease off warnings on the franchise. ... A year ago, regulators slapped warnings to the labelling for Johnson &Johnson’s diabetes drug Invokana

  • The year of the blockbuster The year of the blockbuster

    entrant to an increasingly crowded market and will compete directly with first-to-market Invokana, as well as Farxiga and Jardiance.

  • FDA starts review of Sanofi’s oral type 1 diabetes drug FDA starts review of Sanofi’s oral type 1 diabetes drug

    The idea is that the dual targeting may provide added glucose control with fewer side effects relative to selective SGLT2 inhibitors, such as Johnson &Johnson’s Invokana (pictured), Eli Lilly/Boehringer

  • FDA’s year-end approvals take annual tally to 46 FDA’s year-end approvals take annual tally to 46

    established drugs Johnson &Johnson’s first-to-market blockbuster Invokana (canagliflozin) - which brought in more than $1.2bn last year - fast-gaining rival Jardiance (empagliflozin) from Eli Lilly and Boehringer Ingelheim

  • J&J seeks US OK to add CV claim to Invokana label J&J seeks US OK to add CV claim to Invokana label

    Johnson &Johnson has moved swiftly ahead with a filing for its diabetes drug Invokana that would include a claim that it can reduce major adverse cardiovascular events (MACE). ... s drug has the most to gain from cardiovascular labelling, threatening

More from news
Approximately 18 fully matching, plus 36 partially matching documents found.

Latest Intelligence

  • Market dynamics, marketing and analytics Market dynamics, marketing and analytics

    Forxiga and Invokana (canagliflozin) appear to be reaching a plateau but at different lower levels. ... In contrast Jardiance and Vipidia are still growing where Jardiance (the 3rd entrant SGLT2) appears to have overtaken Invokana (the 2nd entrant).

  • Interview: Christopher Boulton, AstraZeneca Interview: Christopher Boulton, AstraZeneca

    Forxiga is set to face competition from other SGLT2 inhibitors either recently approved or on the horizon, including Janssen/Mitsubishi Tanabe's Invokana (canagliflozin), Sanofi/Chugai's tofogliflozin and

  • Pharma deals during April 2013 Pharma deals during April 2013

    Clearly the pressure is on, the announcement coming only a month after Johnson &Johnson obtained US approval for its SGLT2 inhibitor— Invokana (canagliflozin).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics